Evidence map›Paper›PMID 40653606›Full record

ArticleCancer medicine2025

Knockdown of p53 Enhances LncRNA A2M-AS1 Inhibition of Pancreatic Cancer Progression via Regulating MAPK Pathway.

Yu Cen, Yihui Luo, Yi Nan, Wenxi Kuang, Xianglian Zhang, Jiexia Lu, Chunxiao Xie, Mingzhi Xie, Enran Chen, Haixing Jiang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yu CenDepartment of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yihui LuoDepartment of Gastroenterology, Liuzhou People's Hospital, Liuzhou, China.
Yi NanDepartment of Gastroenterology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Province, China.
Wenxi KuangDepartment of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Xianglian ZhangDepartment of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Jiexia LuDepartment of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Chunxiao XieDepartment of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Mingzhi XieDepartment of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Enran ChenDepartment of General Medicine, Guangxi Medical University, Nanning, China.
Haixing JiangDepartment of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Shanyu QinDepartment of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.ORCID https://orcid.org/0000-0002-8906-964X

Funding

the "139" Plan for Training High-Level Cadre Talents in Guangxi Medicine #G201903004the National Natural Science Foundation of China #81960439the Project of Education Department of Guangxi Zhuang Autonomous Region #2018KY0278the Project of Education Department of Guangxi Zhuang Autonomous Region #2021KY0083the Project of Guangxi University of Chinese Medicine #2018QN031the School-level Project of Guangxi Medical University 1GXMUYSF201825the Self-funded Research Project of Guangxi Zhuang Autonomous Region Health Commission #Z2016322
6 · The paper itself

Abstract

purposeRapid progression in late-stage is a characteristic of pancreatic cancer (PC), leading to mortality. The critical role of lncRNA A2M-AS1 (long non-coding RNA alpha-2-macroglobulin antisense RNA 1) is involved in cancer progression, but the upstream regulator of A2M-AS1 in the PC progression phenotype remains elusive.

methodsWe conducted an integrated analysis using bioinformatics, in vitro experiments, and in vivo studies. Human PC tissues were analyzed for A2M-AS1 and p53 expressions. The PANC-1 and BxPC-3 cell lines were used for functional assays, including cell proliferation, apoptosis, migration, and invasion assays. The role of p53 in regulating A2M-AS1 was investigated through overexpression and knockdown studies, along with using a MAPK pathway inhibitor.

resultsWe found that A2M-AS1 is downregulated in PC tissues and that its high expression correlates with a better prognosis. p53 was identified as a negative regulator of A2M-AS1, with its knockdown leading to increased A2M-AS1 expression and decreased PC cell invasiveness. Mechanistically, p53 was shown to bind to the A2M-AS1 promoter, modulating its transcriptional activity. The MAPK pathway was revealed as a downstream effector of the p53-A2M-AS1 axis, with its inhibition reversing the effects on PC cell behavior.

conclusionHigh A2M-AS1 expression is associated with a better PC prognosis. A2M-AS1 overexpression subdues PC cell development. Our study unveils a new mechanism by which p53 decreases A2M-AS1 expression.

Indexed as

MAP Kinase Signaling SystemPancreatic NeoplasmsRNA, Long NoncodingTumor Suppressor Protein p53AnimalsApoptosisCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMaleMiceRNA, Long NoncodingTP53 protein, humanTumor Suppressor Protein p53LncRNA A2M‐AS1p53pancreatic cancertherapeutic target

Identifiers

PMID40653606
PMCPMC12256274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.